Dengue virus, a flavivirus, is the most common arbovirus infection in the world, with recent estimates of 390 million cases of dengue infection in the world per year, with the majority of them being asymptomatic.
Dengue is coming! Dengue virus, a flavivirus, is the most common arbovirus infection in the world, with recent estimates of 390 million cases of dengue infection in the world per year, with the majority of them being asymptomatic. 1 Classic dengue fever is usually a self-limited illness, but it can give rise to a life-threatening hemorrhagic fever. Both central and peripheral nervous system involvement occurs with dengue virus infection. The dengue virus vector is either the day-feeding mosquito Stegomyia (formerly Aedes 2 ) aegypti or, less commonly, Stegomyia albopictus, both of which are endemic in the continental United States, particularly in the Southeast but present also in other regions. 3 Epidemics of assumed dengue virus infection have been reported in the United States since 1780, when an epidemic occurred in Philadelphia, with the last epidemic reported in 1945, in Louisiana (summarized by Anez and Rios 3 ). Currently, many cases of dengue virus infection are diagnosed in travelers who acquired the disease outside the continental United States. However, autochthonous (locally acquired), as opposed to imported, cases of dengue were recognized in recent years in both Florida and Texas. Thus in the United States dengue is an emerging, or re-emerging, infectious disease that has the potential for major neurologic complications.
Sahu et al. 4 in this issue of Neurology ® present a prospective study of neurologic complications of dengue virus infection in the Lucknow region of India. There were 484 patients collected over slightly more than a 2-year period, with many patients age 20 years or younger, with 3-month follow-up. People who became ill were diagnosed using revised criteria published in 2009 by the WHO, which included neurologic dysfunction for the first time. 5, 6 Patients in the Lucknow study were classified as having CNS disorders (28 patients), peripheral nervous system (PNS) disorders (17 patients), or neither, with an overall incidence of neurologic complications in 9.26% of those studied (45 patients). The majority of neurologically affected patients were diagnosed with encephalitis or encephalopathy. Two patients in the CNS group died, with 3 deaths in the neurologically intact group and none in the PNS group.
The authors were particularly concerned about identifying predictors of neurologic involvement, for which they report several for both of the neurologically impaired groups. But the predictors identified in the study were not specifically neurologic; rather, they were systemic markers such as body temperature, rash, or hematologic values. This implies that the neurologic complications that were observed, such as encephalopathy, were associated with systemic complications of infection. It seems surprising that surviving patients in both the CNS and PNS groups had no long-term neurologic sequelae. However, that may be consistent with the finding of systemic rather than neurologic predictors of neurologic involvement during the course of the illness.
That neurologic involvement occurs during the course of dengue virus infection is not unexpected, since dengue is a flavivirus, as are Japanese encephalitis virus and West Nile virus, with yellow fever virus and hepatitis C virus also belonging to this family of viruses.
There is conflicting information in the literature about whether dengue virus is truly neurotropic. The study by Sahu et al. provides more information on the incidence and spectrum of neurologic complications of dengue infection. However, the study does not provide conclusive evidence that neurologic complications require viral invasion of the nervous system, whether peripheral or central. Further study, including in vitro and animal models, is needed in order to determine whether the neurologic changes described in the Sahu et al. article are due to direct infection of the nervous system by the virus or whether they are manifestations of systemic infection, autoimmunity, or some other mechanism.
With regard to management of dengue virus infection, no specific antiviral therapy is currently available, compared with recent successes in managing the flavivirus hepatitis C virus. 7 Vaccines to prevent dengue have met with only partial success, at best. 7 Clinicians in the United States should be alert for dengue virus infection, not only in parts of the country that are endemic but elsewhere, including in people who have had recent travel to tropical regions (for example, the Caribbean, Mexico, Central America, northern South America, Brazil) where dengue is common. Neurologists can expect to be consulted for patients with dengue who develop CNS and PNS complications.
